Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR Public Health and Surveillance

Date Submitted: Jul 16, 2026
Open Peer Review Period: Jul 21, 2026 - Sep 15, 2026
(currently open for review)

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Drug-Related Mortality in Spain (2001–2022): Trends Across Five Operational Definitions

  • Santiago Martínez-Torre; 
  • Marta Donat; 
  • Pablo Prego-Meleiro; 
  • Julieta Politi; 
  • Gregorio Barrio; 
  • Ana Sarasa-Renedo; 
  • Luis Sordo

ABSTRACT

Background:

Drug-related mortality is monitored using operational definitions that vary across surveillance systems and settings, usually based on ICD-10 codes. These definitions vary in scope and inclusiveness, which may affect the magnitude of estimates and their comparability across countries.

Objective:

This study evaluates how five ICD-10-based surveillance definitions used by national and international monitoring agencies affect estimates and temporal trends in drug-related mortality in Spain.

Methods:

We conducted a repeated cross-sectional analysis of all deaths among Spanish residents recorded in the national mortality register of Spain (INE) during 2001–2022; drug-related deaths were identified separately under each operational definition. Five operational definitions that combine specific subsets of ICD-10 codes were applied: Spain’s National Plan on Drugs (PND), the European Union Drugs Agency (EUDA), the US Centers for Disease Control and Prevention (CDC), the UK Office for National Statistics (ONS), and an Australian/Penington Institute framework (AUS). Annual counts, total deaths, annual means, average annual change (AAC), and Spearman correlations were computed overall and stratified by gender and age (<35, 35–64, ≥65).

Results:

All five definitions showed broadly concordant temporal trends, with a marked increase after 2016. Differences between definitions affected primarily the absolute number of deaths, with PND yielding the lowest counts and AUS yielding the highest. In the general population, total deaths ranged from 14,298 under PND to 28,217 under AUS, and Spearman correlations with PND ranged from 0.84 to 0.95. Across strata, correlations were generally high, although lower values were observed for CDC in some groups. By gender, trends were coherent across definitions, with moderate increases in men and faster growth in women. By age, deaths declined among people aged <35 years and increased among those aged 35–64 and ≥65 years, with the largest absolute increases in the 35–64 group.

Conclusions:

Applying different operational definitions to the same Spanish mortality dataset substantially changed the estimated burden of drug-related mortality, nearly doubling counts under the broadest definition. However, temporal patterns were broadly consistent across definitions. Transparent and harmonized ICD-10 code sets are needed to improve international comparability.


 Citation

Please cite as:

Martínez-Torre S, Donat M, Prego-Meleiro P, Politi J, Barrio G, Sarasa-Renedo A, Sordo L

Drug-Related Mortality in Spain (2001–2022): Trends Across Five Operational Definitions

JMIR Preprints. 16/07/2026:107250

DOI: 10.2196/preprints.107250

URL: https://preprints.jmir.org/preprint/107250

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.